Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
30 08 2022
30 08 2022
Historique:
received:
17
03
2022
accepted:
05
08
2022
entrez:
30
8
2022
pubmed:
31
8
2022
medline:
3
9
2022
Statut:
epublish
Résumé
The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is key for translation from promising in vitro results to successful clinical implementation. Among the drugs that have been largely tested in clinical trials but failed so far to bring clear evidence of clinical efficacy is favipiravir, a nucleoside analogue with large spectrum activity against several RNA viruses in vitro and in small animal models. Here, we evaluate the antiviral activity of favipiravir against Zika or SARS-CoV-2 virus in cynomolgus macaques. In both models, high doses of favipiravir are initiated before infection and viral kinetics are evaluated during 7 to 15 days after infection. Favipiravir leads to a statistically significant reduction in plasma Zika viral load compared to untreated animals. However, favipiravir has no effects on SARS-CoV-2 viral kinetics, and 4 treated animals have to be euthanized due to rapid clinical deterioration, suggesting a potential role of favipiravir in disease worsening in SARS-CoV-2 infected animals. To summarize, favipiravir has an antiviral activity against Zika virus but not against SARS-CoV-2 infection in the cynomolgus macaque model. Our results support the clinical evaluation of favipiravir against Zika virus but they advocate against its use against SARS-CoV-2 infection.
Identifiants
pubmed: 36042198
doi: 10.1038/s41467-022-32565-w
pii: 10.1038/s41467-022-32565-w
pmc: PMC9427089
doi:
Substances chimiques
Amides
0
Antiviral Agents
0
Pyrazines
0
favipiravir
EW5GL2X7E0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5108Informations de copyright
© 2022. The Author(s).
Références
PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389
pubmed: 28231247
EBioMedicine. 2021 Jan;63:103204
pubmed: 33418497
Nat Commun. 2021 Sep 1;12(1):5215
pubmed: 34471122
Cell. 2021 Mar 4;184(5):1188-1200.e19
pubmed: 33577765
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Antimicrob Agents Chemother. 2016 Dec 27;61(1):
pubmed: 27736754
Front Cell Infect Microbiol. 2022 Jun 14;12:838213
pubmed: 35774397
EBioMedicine. 2021 Oct;72:103595
pubmed: 34571361
PLoS Comput Biol. 2021 Jan 7;17(1):e1008535
pubmed: 33411731
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):8847-8852
pubmed: 28765371
Antiviral Res. 2020 Sep;181:104878
pubmed: 32679055
Drug Metab Dispos. 1975 Jul-Aug;3(4):259-65
pubmed: 240655
Hepatol Forum. 2021 Sep 15;2(3):122-127
pubmed: 35784909
PLoS Med. 2016 Mar 01;13(3):e1001967
pubmed: 26930627
Cell Host Microbe. 2021 Sep 8;29(9):1437-1453.e8
pubmed: 34428428
Antimicrob Agents Chemother. 2014 Jul;58(7):3950-6
pubmed: 24798284
CPT Pharmacometrics Syst Pharmacol. 2020 May;9(5):258-271
pubmed: 32198838
Hepatol Int. 2022 Aug;16(4):755-774
pubmed: 35767172
Nat Commun. 2020 Sep 17;11(1):4682
pubmed: 32943628
Antimicrob Agents Chemother. 2020 Jun 23;64(7):
pubmed: 32366720
Emerg Infect Dis. 2008 Aug;14(8):1232-9
pubmed: 18680646
J Virol. 2015 Sep;89(17):8880-96
pubmed: 26085147
Clin Pharmacokinet. 2016 Aug;55(8):907-23
pubmed: 26798032
Antimicrob Agents Chemother. 2021 Mar 1;:
pubmed: 33649117
Clin Infect Dis. 2022 Apr 21;:
pubmed: 35446944
Nat Commun. 2021 Mar 19;12(1):1735
pubmed: 33741945
Clin Infect Dis. 2021 Aug 2;73(3):531-534
pubmed: 32770240
Antiviral Res. 2018 Mar;151:97-104
pubmed: 29289666
Nature. 2020 Sep;585(7826):584-587
pubmed: 32698191
Gut. 2022 Jun 14;:
pubmed: 35701093
Infect Dis Ther. 2021 Dec;10(4):2489-2509
pubmed: 34453234
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
PLoS Med. 2018 Mar 27;15(3):e1002535
pubmed: 29584730
Clin Microbiol Infect. 2022 Apr;28(4):602-608
pubmed: 35026375
Nat Commun. 2021 Oct 20;12(1):6097
pubmed: 34671037
Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955-26965
pubmed: 33037151